Howland Capital Management LLC Boosts Stake in Stryker Corporation $SYK

Howland Capital Management LLC increased its position in Stryker Corporation (NYSE:SYK) by 2.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 102,127 shares of the medical technology company’s stock after purchasing an additional 2,132 shares during the period. Stryker accounts for about 1.4% of Howland Capital Management LLC’s holdings, making the stock its 20th biggest holding. Howland Capital Management LLC’s holdings in Stryker were worth $35,984,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Czech National Bank increased its position in Stryker by 3.9% during the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after purchasing an additional 3,366 shares during the period. Davis R M Inc. grew its holdings in shares of Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after acquiring an additional 2,512 shares during the period. Kepler Cheuvreux Suisse SA acquired a new stake in shares of Stryker in the 3rd quarter worth approximately $27,952,000. Daymark Wealth Partners LLC grew its holdings in shares of Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after acquiring an additional 37,307 shares during the period. Finally, Varma Mutual Pension Insurance Co grew its holdings in shares of Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after acquiring an additional 5,100 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Up 2.1%

Shares of Stryker stock opened at $312.14 on Friday. The business has a 50-day moving average of $316.40 and a 200-day moving average of $343.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market capitalization of $119.66 billion, a PE ratio of 36.13, a P/E/G ratio of 1.93 and a beta of 0.78. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Insider Buying and Selling at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on SYK shares. Needham & Company LLC lowered their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. William Blair reissued an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. BTIG Research reduced their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Citigroup reduced their target price on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Finally, Canaccord Genuity Group reduced their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.